There is no evidence that thrombolysis has a benefit over standard anticoagulant treatment in normotensive patients with acute PE, but more research is needed to better identify the subgroup of patients with nonmassive PE in whom the risk-benefit ratio is most favorable. Until this group is defined and the benefit of thrombolytic therapy is demonstrated, thrombolytic therapy should only be considered in patients with signs of massive PE and hemodynamic shock. Semin Thromb Hemost. 2007 Nov;33(8):821-8
Archivado bajo: TVP, Vascular | Etiquetado: Embolia Pulmonar, Trombolisis, TVP
